ERBB2 and neoplasm: For example, it would be worthwhile to retrospectively stratify clinical trial data by proximal vs. distal tumor and see if targeted therapies (like anti-HER2, immune checkpoint inhibitors, or anti-angiogenic agents) show differential efficacy.